+ -0.01
+ 0%
+ 0.55
+ 0.32%

Study Investigates Optimal Dosing For MDMA

April 15, 2021 6:25 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Study Investigates Optimal Dosing For MDMA

This article by Jennifer Walker-Journey was originally published on Psychedelic Spotlight, and appears here with permission.

Potential optimal MDMA dosages for therapeutic benefit and reduced adverse events were investigated in a new study published in the latest edition of the Journal of Psychopharmacology

“To our knowledge, this is the first study on personalized MDMA treatment including pharmacogenetics, personality assessments, and psychometrics in one analysis,” Dr. Matthias Liechti says. 

The research was conducted by clinical-stage psychedelic biotech company MindMed, and took place in Dr. Liechi’s lab at the University Hospital Basel in Switzerland. Researchers used data from 194 MDMA administrations in ten randomized placebo-controlled studies in healthy participants, most of whom had no prior MDMA experience. 

Researchers found that the dosage of MDMA had the greatest impact on an individual’s response. However, genetics, personality, and mood before MDMA use also influenced how a person responded to treatment. Findings include:

  • Participants with low levels of the drug metabolizing enzyme CYP2D6 had higher MDMA concentrations in their blood, suggesting they may benefit from a moderate dose reduction. 
  • People who are more open to new experiences showed more positive drug effects during MDMA treatment. 
  • Conversely, people who were more anxious were more likely to experience fear of ego dissolution and losing control. Similarly, those who were more anxious or depressed just before MDMA administration experienced more anxiety after MDMA administration. 
  • Previous MDMA use did not affect the MDMA effect. 

“With the promise of advances in psychedelic medicine we are aiming to step away from the rather rigid and inflexible drug centric approach of ‘one size fits all’ and start leveraging data and machine learning to help health professionals and patients engage new personalized therapies in the treatment paradigms,” MindMed Executive President, Dr. Miri Halperin Wernli says. “We are building unique biomarker profiles of individuals across genetics, phenotypes, personality traits, and cognitive states that will allow us to best predict which therapy framework configurations will be most effective.”

Read the original Article on Psychedelic Spotlight.

Benzinga's Related Links: 


Cannabis Markets

Related Articles

Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M

Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound. read more

World's First Phase 3 Clinical Trial On MDMA Shows 'Powerful New Pathway To Healing'

The results from the world’s first Phase 3 clinical study on a psychedelic are in — and they’re significant. The Multidisciplinary Association for Psychedelic Studies released the results from its Phase 3 trial on MDMA for the treatment of post-traumatic stress disorder.  read more